JP2009502139A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502139A5
JP2009502139A5 JP2008523043A JP2008523043A JP2009502139A5 JP 2009502139 A5 JP2009502139 A5 JP 2009502139A5 JP 2008523043 A JP2008523043 A JP 2008523043A JP 2008523043 A JP2008523043 A JP 2008523043A JP 2009502139 A5 JP2009502139 A5 JP 2009502139A5
Authority
JP
Japan
Prior art keywords
seq
sequence
light chain
amino acid
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008523043A
Other languages
English (en)
Japanese (ja)
Other versions
JP4997239B2 (ja
JP2009502139A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/028702 external-priority patent/WO2007014169A2/en
Publication of JP2009502139A publication Critical patent/JP2009502139A/ja
Publication of JP2009502139A5 publication Critical patent/JP2009502139A5/ja
Application granted granted Critical
Publication of JP4997239B2 publication Critical patent/JP4997239B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008523043A 2005-07-22 2006-07-24 抗cd26抗体およびその使用方法 Expired - Fee Related JP4997239B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70180205P 2005-07-22 2005-07-22
US60/701,802 2005-07-22
PCT/US2006/028702 WO2007014169A2 (en) 2005-07-22 2006-07-24 Anti-cd26 antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2009502139A JP2009502139A (ja) 2009-01-29
JP2009502139A5 true JP2009502139A5 (2) 2009-09-10
JP4997239B2 JP4997239B2 (ja) 2012-08-08

Family

ID=37683891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008523043A Expired - Fee Related JP4997239B2 (ja) 2005-07-22 2006-07-24 抗cd26抗体およびその使用方法

Country Status (11)

Country Link
US (2) US7462698B2 (2)
EP (1) EP1907425B1 (2)
JP (1) JP4997239B2 (2)
KR (1) KR20080039929A (2)
CN (1) CN101282994B (2)
AU (1) AU2006272713A1 (2)
BR (1) BRPI0613770A2 (2)
CA (1) CA2615615A1 (2)
IL (1) IL188748A0 (2)
RU (1) RU2486204C2 (2)
WO (1) WO2007014169A2 (2)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1907425B1 (en) 2005-07-22 2014-01-08 Y's Therapeutics Co., Ltd. Anti-cd26 antibodies and methods of use thereof
EP2131863A4 (en) 2007-03-14 2012-07-11 Univ Tokyo METHOD FOR THE TREATMENT OF MALIGNEM MESOTHELIOM
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
EP2749641B1 (en) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
US11242399B2 (en) 2013-02-19 2022-02-08 Adienne S.A. Anti-CD26 antibodies
JP2015030666A (ja) * 2013-07-31 2015-02-16 学校法人順天堂 抗ヒトcd26モノクローナル抗体又はその抗原結合性断片
US20160193308A1 (en) * 2013-09-04 2016-07-07 Osaka University Dpp-4-targeting vaccine for treating diabetes
CN103641917B (zh) * 2013-12-09 2015-07-01 江苏众红生物工程创药研究院有限公司 抗cd26抗体及其应用
CN103709251B (zh) * 2013-12-19 2016-04-13 江苏众红生物工程创药研究院有限公司 全人源抗cd26抗体及其应用
CN103694352B (zh) * 2013-12-19 2015-12-09 江苏众红生物工程创药研究院有限公司 一种抗 cd26 抗体及其制备方法
CN103724431B (zh) * 2014-01-16 2016-03-30 江苏众红生物工程创药研究院有限公司 一种人源抗cd26抗体及其应用
TWI677505B (zh) * 2014-08-18 2019-11-21 瑞士商艾迪安納股份有限公司 抗cd26抗體及其用途
AU2016205188A1 (en) * 2015-01-09 2017-06-22 Medimmune, Llc Assay to detect human DPP-4
JP6931228B2 (ja) * 2015-09-11 2021-09-01 ワイズ・エー・シー株式会社 抗cd26抗体と他の抗癌剤とを組み合わせた癌治療用組成物
CN107207608B (zh) * 2015-10-30 2021-05-11 江苏众红生物工程创药研究院有限公司 双特异性抗体、其制备方法和用途
WO2017175086A1 (en) * 2016-04-05 2017-10-12 Pfizer Inc. Cell culture process
EP3490605B1 (en) 2017-04-01 2023-06-07 AVM Biotechnology, LLC Replacement of cytotoxic preconditioning before cellular immunotherapy
KR102194025B1 (ko) 2017-12-15 2020-12-22 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
CN110128539A (zh) * 2018-02-02 2019-08-16 中国药科大学 抗二肽基肽酶4的单克隆抗体及其制备方法和用途
JP7064203B2 (ja) * 2018-03-16 2022-05-10 学校法人順天堂 抗ヒトcd26モノクローナル抗体
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
CN109709337B (zh) * 2018-12-28 2021-09-14 江苏众红生物工程创药研究院有限公司 人cd26的免疫组化检测试剂盒及其临床应用
EP4034561A2 (en) * 2019-09-27 2022-08-03 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
US11723926B2 (en) 2019-09-27 2023-08-15 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
US20250340665A1 (en) 2021-05-13 2025-11-06 Adienne S.A. Methods of treating dermatomyositis
KR20240007229A (ko) 2021-05-13 2024-01-16 아디에네 에스.에이. 이식편 대 숙주 질환을 치료하는 방법
CN116023491A (zh) * 2021-10-25 2023-04-28 江苏众红生物工程创药研究院有限公司 抗cd26抗体及其应用
CN116549629A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 Cd45作为生物标志物在筛查cd26抗体或其衍生物治疗肿瘤有效性和精准性中的应用

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5120642A (en) 1989-11-28 1992-06-09 Coulter Corporation Monoclonal antibody which distinguishes helper inducer and suppressor inducer cd4+ lymphocytes
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
AU7766391A (en) * 1990-04-23 1991-11-11 Corvas International N.V. Thrombus-specific antibody derivatives
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
WO1993016102A1 (en) 1992-02-06 1993-08-19 Dana-Farber Cancer Institute, Inc. Human cd26 and methods for use
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
WO1994009132A1 (en) 1992-08-21 1994-04-28 Dana-Farber Cancer Institute, Inc. Human cd26 and methods for use
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE4330971A1 (de) 1993-09-13 1995-03-16 Basf Ag Copolymerisate sowie deren Reaktionsprodukte mit Aminen als Kraftstoff- und Schmierstoffadditiv
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6265551B1 (en) 1995-06-01 2001-07-24 Dana-Farber Cancer Institute, Inc. Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof
US6325989B1 (en) 1995-06-01 2001-12-04 Dana-Farber Cancer Institute, Inc. Form of dipeptidylpeptidase IV (CD26) found in human serum
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US20030022240A1 (en) 2001-04-17 2003-01-30 Peizhi Luo Generation and affinity maturation of antibody library in silico
EP1390741B1 (en) 2001-04-17 2012-10-31 Abmaxis, Inc. Structure-based construction of human antibody library
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20040010376A1 (en) 2001-04-17 2004-01-15 Peizhi Luo Generation and selection of protein library in silico
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
KR100863624B1 (ko) * 2001-05-11 2008-10-15 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Cd26을 발현하는 세포와 연관된 질환의 치료제로사용되는 항-cd26 단클론항체
US20030138429A1 (en) * 2001-05-22 2003-07-24 Pizzo Salvatore V. Compositions and methods for inhibiting metastasis
WO2003054172A2 (en) 2002-01-17 2003-07-03 Lonza Biologics Plc. Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
GB0208041D0 (en) 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
EP1575519A2 (en) 2002-05-17 2005-09-21 Board Of Regents, The University Of Texas System Cd26-based therapies for cancers and immune disease
WO2003099999A2 (en) 2002-05-20 2003-12-04 Abmaxis, Inc. Generation and selection of protein library in silico
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
US20040220084A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Methods for nucleic acid delivery
WO2005058244A2 (en) * 2003-12-15 2005-06-30 Alexion Pharmaceuticals, Inc. Novel anti-dc-sign antibodies
WO2005063170A2 (en) 2003-12-29 2005-07-14 Toudai Tlo, Ltd. Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
EP1907425B1 (en) 2005-07-22 2014-01-08 Y's Therapeutics Co., Ltd. Anti-cd26 antibodies and methods of use thereof
PT1931350E (pt) 2005-09-14 2014-02-12 Takeda Pharmaceutical Administração de inibidores de dipeptidil peptidase

Similar Documents

Publication Publication Date Title
JP2009502139A5 (2)
RU2008106760A (ru) Антитела против сd26 и способы их применения
JP2023509196A5 (2)
JP2014158469A5 (2)
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
RU2013125306A (ru) Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование
ME02371B (me) Sastojci i postupci za dijagnstikovanje i tretman raka
CN116396386A (zh) Cd3抗体及其药物用途
RU2017105915A (ru) Антитела против pd-1
RU2018145852A (ru) Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
RU2010132956A (ru) Ангиопоэтин-2-специфические связывающие агенты
JP2019535250A5 (2)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2011207882A5 (2)
JP2014530017A5 (2)
JP2019532619A5 (2)
JP2017523786A5 (2)
CA2583910A1 (en) Angiopoietin-2 specific binding agents
NZ568403A (en) CD20-specific antibodies and methods of employing same
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
JP2010504755A5 (2)
CA2595610A1 (en) Antibodies directed to angiopoietin-2 and uses thereof
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
JP2012532851A5 (2)